A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obsessive-compulsive disorder (OCD) is a common debilitating psychiatric illness that typically improves but does not remit with first-line medication and behavioral treatments. Serotonergic agents including selective serotonin reuptake inhibitors and clomipramine have provided the mainstay of OCD medication management for decades. Combined dopamine/serotonergic agents such as atypical antipsychotics are presently the only OCD-augmenting strategies proven effective via randomized controlled trials. Despite increasing evidence for a pathogenic role of glutamate in OCD, no controlled trials of glutamatergic augmenting agents have been reported. METHODS: An intent-to-treat sample included 44 subjects receiving standard treatment at the McLean/Massachusetts General Hospital Intensive Residential Treatment (IRT) program, 22 of whom also received memantine augmentation. Admission, monthly and discharge measures of OCD, depression, and psychosocial functioning were collected by raters blinded to augmentation status. Matched controls were selected based on sex, initial OCD severity, psychosocial functioning, and timing of admission. The Clinical Global Improvement Scale captured global clinical change. RESULTS: Mean (SD) Yale-Brown Obsessive Compulsive Scale score decreases were 7.2 (6.4) among the cases and 4.6 (5.9) among the matched controls, reflecting mean clinical improvement among the cases (27.0% decrease) but not the controls (16.5% decrease). Mean (SD) depression severity score decreases were 5.8 (9.5) among the cases and 4.7 (9.9) among the controls. Initial intrusive obsessions were significantly more severe among marked responders compared with limited response or nonresponse cases (4.4 vs 2.9; t = 2.15; P = 0.048). CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Future randomized double-blind placebo-controlled trials are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Memantine add-on to fluvoxamine significantly improved short-term outcomes in patients with moderate to severe OCD”
From The neurobiological link between OCD and ADHD (2014) · cites this paper as Stewart et al. 2010
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 1×
“76, sensitivity of 100%, and specificity of 89% (using a cutoff score of 16).(22,40,41) The Obsessive-Compulsive Rating scale is a questionnaire-based measure that rates the severity of OCD symptom categories between 0 and 10.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515 · cited 1×
“86, and increasing scores that reflect worse functional impairment.(43) The Clinical Global Impression (CGI) scale provides an assessment of overall impact of treatment rated between 1 (very much improved) and 7 (very much worse).”
BackgroundThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048 · cited 1×
“First-line OCD treatments, including selective serotonin reuptake inhibitors (SSRIs), cognitivebehavior therapy (CBT), and their combination, are effective in approximately 42% to 50%,(3) 62%, and 70% of cases, respectively.(4) However, symptoms often persist and full remission is uncommon with first-line approaches.”
BackgroundCortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · cited 1×
“Knockout mice for the striatum-expressed SAPAP3 gene, coding for a postsynaptic scaffolding protein at corticostriatal glutamatergic excitatory synapses, also developed facial lesions, repetitive grooming behaviors, and anxiety that were reversed with an SSRI and with gene replacement.(33) Memantine is a glutamate rec…”
BackgroundSynopsis of Psychiatry: 5th edn. Behavioral Sciences Clinical Psychiatry
Kaplan, H. I., & Sadock, B. J. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198907000-00008 · Cited by 852
Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder
Saxena, S., & Rauch, S. L. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70181-7 · Cited by 840 · cited 1×
“24 Moreover, glutamate receptor antagonism leads to an enhancement of 5-HT2A receptorYmediated transmission; 5-HT2A agonism leads to reduced glutamatergic transmission(24) and 5-HT receptor activation reduces the excitatory effect of glutamate on cellular activity.(50) It is this interaction that is believed to contri…”
Background
Cited by
Items 101–159 of 159
Memantine for Posttraumatic Stress Disorder in an Older Veteran
Chopra, M. P., Trevino, K. M., & Kowall, N. W. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823657bf · Cited by 11
Pekrul, S. R., & Fitzgerald, K. D. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0073 · Cited by 9
“More recently, there is emerging evidence that glutamatergic agents such as memantine are effective in treatment-resistant OCD in both adult and pediatric OCD patients (Pasquni and Bodni 2006; Aboujaoude, Barry, Gamel, 2009; Hezel et al. 2009; Stewart et al. 2010).”
Abdel-Ahad, P., & Kazour, F. (2015) · Current Clinical Pharmacology · doi:10.2174/15748847113089990060 · Cited by 13
Wolmarans, D. W., Stein, D. J., & Harvey, B. H. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170523125256 · Cited by 11
Evidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., Brown, A., & Pampaloni, I. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.009 · Cited by 9
Grassi, G., Scillitani, E., & Cecchelli, C. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387127 · Cited by 8
“Several early case reports and a few open label trials showed promising results more than a decade ago [78–83].”
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research
Koran, L. M., & Aboujaoude, E. N. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170526120916 · Cited by 10
Niemeyer, L., Mechler, K., Dittmann, R., Banaschewski, T., Buitelaar, J. K., Durston, S., & Häge, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100982 · Cited by 9
“5% (placebo group) in their single-blinded case-control study on adults with severe obsessive-compulsive disorder [43].”
BackgroundAkimoto, T., Sutoh, C., Kuno, M., Matsuzawa, D., Niitsu, T., Iyo, M., & Shimizu, E. (2021) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2021.111003 · Cited by 7
“, riluzole [21] [22], memantine [23] [24] [25], and ketamine [26]) have been shown to have potential efficacy for decreasing the severity of OCD symptoms.”
BackgroundDallaspezia, S., Mazza, M., Lorenzi, C., Benedetti, F., & Smeraldi, E. (2014) · European psychiatry · doi:10.1016/j.eurpsy.2014.02.006 · Cited by 7
“Finally, open label studies and case reports suggest that glutamatergic agents, such as riluzole [16], memantine [21] and N-acetylcysteine[11], might have therapeutic effects in OCD.”
BackgroundPavlovic, Z. M. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.3.e42 · Cited by 7
“Furthermore, an open-label clinical study was conducted with memantine, showing its positive effects on OCD symptoms.(9) Our patient, “Mr.”
MethodBernhardt, E. B., Walsh, K. H., Posey, D. J., & McDougle, C. J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c92d4 · Cited by 7
Janikova, M., Brožka, H., Radostová, D., Svoboda, J., & Stuchlík, A. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.01.013 · Cited by 7
Treatment of Psychiatric Comorbidities in Tourette Syndromes
Cardona, F., & Rizzo, R. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0025 · Cited by 6
A New Appraisal of Combined Treatments for PTSD in the Era of Psychotherapy Adjunctive Medications
Sheerin, C. M., Seim, R. W., & Spates, C. R. (2011) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-011-9195-z · Cited by 6
Murphy, T. K., Stewart, S. E., & Obregon, D. F. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_10 · Cited by 9
Self-citationMirzazadeh, H., Ghaeminia, Y., Niaei, A. M., Kamran, M., Jahromi, L. R., & Moshfeghinia, R. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06856-7 · Cited by 5
“Several randomized clinical trials (RCTs) and reviews have shown the beneficial role of memantine in the management of OCD in combination with SSRIs [11, 29–31].”
Amantadine and antiglutamatergic drugs in the management of Parkinson's disease
ONOFRJ, M. C., Frazzini, V., Bonanni, L., & Thomas, A. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.003 · Cited by 4
Treatment-Resistant Obsessive-Compulsive Disorder (OCD) – Current Understanding
Mushtaq, A., Chandel, R. K., Mushtaq, H., & Mushtaq, D. (2014) · InTech eBooks · doi:10.5772/57232 · Cited by 6
“A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD [75].”
ResultObsessive-Compulsive and Related Disorders
Pato, M. T., Arnold, P. D., Zohar, J., Bitan, S., Klein, K. P., & Eisen, J. L. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_23-1 · Cited by 3
Bryan, J., & Hassoulas, A. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07787-7 · Cited by 2
“Existing literature suggests that greater baseline severity is generally associated with poorer treatment response [22, 30], which may partially account for variability in reported outcomes across trials.”
The Use of Glutamate Modulating Drugs in Obsessive Compulsive Disorder
MacMaster, F. P., & Rosenberg, D. R. (2010) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2010.15.6.1 · Cited by 2
“Finally, a single blind case control study found that memantine augmentation was more effective than intent to treat alone (Stewart et al., 2010).”
BackgroundAdvances in Pharmacotherapy for Pediatric Anxiety Disorders
Rynn, M. A., Puliafico, A. C., Heleniak, C. M., Rikhi, P., Ghalib, K., & Vidair, H. B. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.3.foc299 · Cited by 2
Role of Glutamatergic Modulators in the Treatment of Obsessive Compulsive and Related Disorders
Çelik, F. G. H., & Hocaoğlu, Ç. (2024) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1279927 · Cited by 2
Progrès récents dans le traitement des troubles anxieux.
Antony, M. M. (2011) · Canadian Psychology/Psychologie canadienne · doi:10.1037/a0022376 · Cited by 3
Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch5 · Cited by 1
Özen, M. E., Kalenderoğlu, A., Çelik, M., Örüm, M. H., & Hocaoğlu, Ç. (2019) · Adıyaman Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30569/adiyamansaglik.477617 · Cited by 5
Phenomenology and Standard Care of OCD in Children and Adolescents
Greenberg, E., & GELLER, D. A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108235655.014 · Cited by 3
Memantine for autism spectrum disorder
Brignell, A., Prakash, C., Marraffa, C., Williams, K. J., & May, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013845 · Cited by 2
Use of N-acetylcysteine in Obsessive-Compulsive and Related Disorders
Memik, N. Ç., Gündoğdu, Ö. Y., & Tural, Ü. (2015) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20140811064455 · Cited by 2
Child and Adolescent Psychiatric Disorders
Thom, R. P., Prince, J. B., & Rubin, D. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00039-4 · Cited by 1
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Obsessive‐Compulsive Disorder: Assessment and Treatment
Abramovitch, A., Elliott, C. M., Wilhelm, S., Steketee, G. S., & Wilson, A. C. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch51 · Cited by 1
Biological Models and Treatments for OCD in Adults
Stewart, S. E., & Loh, A. S. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch14 · Cited by 1
Self-citationGlutamate and the Treatment of Obsessive-Compulsive Disorder
MacMaster, F. P., & Rosenberg, D. R. (2010) · Psychopharm Review · doi:10.1097/01.idt.0000371059.45965.88 · Cited by 2
Psychopharmacology for Pediatric OCD and Related Disorders
Greenberg, E., Johnson, G., & GELLER, D. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_10 · Cited by 1
Family Medicine & Medical Science Research
Alrajeh, N. A., & Arabia, S. (2012) · Family Medicine & Medical Science Research · doi:10.4172/2327-4972
Katzman, M. A., Bleau, P., Blier, P., Chokka, P. R., Kjernisted, K. D., & Ameringen, M. V. (2023) · doi:10.32920/14638581.v1 · Cited by 1
Cellular Mechanism of Obsessive-Compulsive Disorder
Tee, L. Y. (2015) · DukeSpace (Duke University)
Obsessive–Compulsive and Related Disorders: Obsessive–Compulsive Disorder and Hoarding Disorder
Pato, M. T., Steketee, G. S., Eisen, J. L., Yip, A. G., & Phillips, K. A. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch57
Atypical Psychopharmacologic Strategies
Shatkin, J. P., & Janssen, A. C. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch15
Il trattamento del disturbo ossessivo-compulsivo resistente
Aguglia, A., Albert, U., Cori, D. D., Maina, G., & Bogetto, F. (2011) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2010.12.003
Worsening Tics as a Possible Side Effect of Memantine
Katzman, M. (2013) · Family Medicine & Medical Science Research · doi:10.4172/2327-4972.1000105
“Recently, our clinic has observed a 26 year old male patient with severe treatment resistant obsessive compulsive disorder (OCD) who has developed a greater frequency of tics, as a possible side effect of memantine as an add on to his other medications.”
BackgroundInfluentialPallanti, S., Grassi, G., Cravaro, R., & Goodman, W. K. (2014) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology
Scarff, J. R. (2014) · The Internet Journal of Psychiatry
The Pharmacological Basis for Parkinson's Disease Treatment
(2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.001
Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders
Rodríguez, C. I., & Dakwar, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_9
7.5% carbon dioxide inhalation : modelling anxiety and assessing pharmacological effects
Pinkney, V. (2016) · ePrints Soton (University of Southampton)
N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists
Ogata, N., & Dantas, L. M. D. S. (2019) · Wiley eBooks · doi:10.1002/9781119226253.ch12
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1064
Rosenberg, D. R., Easter, P. C., & Michalopoulou, G. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch10
Nutritional Deficiencies in Obsessive-Compulsive Disorder and Possible Treatment Interventions
Sethi, P., Kumar, S., Prajapati, A., Irfanullah, Z., Jatchavala, C., Vadivel, R., & Hayek, S. E. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-5021-6_9
Treatment of Psychiatric Comorbidities in Tourette Syndrome
Cardona, F., & Rizzo, R. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197543214.003.0027
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_6
Pato, M. T., Arnold, P. D., Zohar, J., Bitan, S., Klein, K. P., & Eisen, J. L. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_23 · Cited by 2
Evaluating the Role of Memantine in the Treatment of Obsessive-Compulsive DisorderPreprint
Bryan, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7320946/v1
Innovative treatment approaches for paediatric obsessive-compulsive disorder
Marazziti, D., Gurrieri, R., Gambini, M., Russomanno, G., Palagini, L., & Mucci, F. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2591073
“Early open-label studies on patients receiving an overall dosage increased to 20 mg/day for 12 weeks did not report a significant difference in terms of the number of patients showing significant clinical improvement [250–252].”
Prados-Pardo, Á. (2023) · Repositorio de Patentes de la Universidad de Almería (Universidad de Almería)
Rostami, H., Dorafshan, Z., Irani, N. S., Mofradnejad, S., & Norouzi, S. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002188
Metadata
- Authors
- Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A.
- Affiliations
- Harvard University (US)
- McLean Hospital (US)
- Tufts University (US)
- Corresponding author
- Stewart, S. Evelyn
- Jenike, Eric A.
- Hezel, Dianne M.
- Stack, Denise Egan
- Jenike, Michael A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-02
- Volume
- 30
- Issue
- 1
- Pages
- 34-39
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2056828397
- Cited by
- 158
- References
- 59
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 2 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 11 · 2014: 13 · 2013: 18 · 2012: 14
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- memantine, obsessive-compulsive disorder, drug augmentation, depression severity, Yale-Brown Obsessive Compulsive Scale, treatment response
- MeSH terms
- Adult, Benzodiazepines, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inpatients, Male, Memantine, Obsessive-Compulsive Disorder, Residential Facilities, Antipsychotic Agents, Case-Control Studies, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.